

DEPARTMENT OF DEFENSE

Defense Health Agency

Intent to Grant an Exclusive License for U.S. Government Co-Owned Invention

AGENCY: Defense Health Agency, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive, royalty-bearing, revocable, license within a field of use.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Paul Michaels, Office of Research &
Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory
Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,
royalty-bearing, revocable license agreement to U.S. Patent 9,375,407 issued on June 28, 2016
entitled “Dimethyl Trisulfide As a Cyanide Antidote” (co-owned by Sam Houston State
University) to Defender Pharmaceuticals, having its principal place of business at 12935 North
Outer Forty Road, Suite 212, St. Louis, Missouri 63141.

Anyone wishing to object to grant of this option can file written objections along with
supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).